Publications

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93

Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010-2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (4): 1982-1988

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 61-68

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2013; 41 (4): 337-342

In vitro activity of a carbapenem and novel beta-lactamase (BL) inhibitor (I) combination (RPX2003/RPX7009) tested against contemporary populations of Gram-negative organisms, Lead author: Castanheira M, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Activity of the Fluoroketolide Solithromycin (SOL) Tested against Bacterial Species Associated with Significant Community-Acquired Bacterial Pneumonia (CABP) and other Gram-positive (GP) organisms, Lead author: Castanheira M, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011), Lead author: Flamm R, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Ceftaroline and Comparator Potency among Nine USA Census Regions: Report from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program, Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin or Vancomycin from USA Hospitals (2008-2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Antimicrobial Activity of Ceftaroline Combined with Avibactam Tested Against Bacteria Collected from Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in USA Medical Centers (2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Activity of the Novel Antimicrobial Combination Ceftolozane/Tazobactam, Tested Against Bacterial Isolates in USA Hospitals from Patients with Pneumonia (2011), Lead author: Sader HS, presented at ID Week, October 17 – 21, 2012, San Diego, CA

Streptococcus sanguinis Displaying a Cross Resistance Phenotype to Several Ribosomal RNA Targeting Agents, Including Linezolid, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Analysis of cfr-carrying Plasmids in Staphylococcus epidermidis and Staphylococcus aureus from Two Hospitals in Ohio, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

IMP-33, a New IMP Variant Detected in Pseudomonas aeruginosa from Italy, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Ceftaroline Activity Tested Against Pathogens Associated With Acute Bacterial Skin and Skin Structure Infections Isolated From Latin American Medical Centers (2010), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Contemporary (2010) Pathogens Associated with Acute Bacterial Skin and Skin Structure Infections Isolated from the Asia-Pacific Region and South Africa, Lead author: Rhomberg PR, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Susceptibility of S. aureus from USA Hospitals According to the Site of Infection: Data from the Ceftaroline AWARE Surveillance Program (2008-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Ceftaroline and Comparator Agent Activity Against Contemporary (2010) Staphylococcus aureus Isolates from Asia-Pacific Region and South Africa Hospitals, Lead author: Rhomberg PR, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Oritavancin Activity Tested Against Staphylococcus aureus and B-hemolytic Streptococci Causing Skin and Skin Structure Infections in the USA (2010-2012), Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Emerging Markets Resistance Surveillance Program Report for Eastern European Nations, Lead author: Jones RN, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Update of Dalbavancin Activity in the USA: Report from the SENTRY Program (2011), Lead author: Jones RN, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2011: USA Surveillance Report, Lead author: Ross JE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of Ceftaroline and Comparator Agents Tested Against Contemporary (2010) Pathogens Commonly Associated With Respiratory Tract Infections in Asia-Pacific Countries and South Africa, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested Against Bacteria Collected from Patients with Community-Acquired Respiratory Tract Infections in the USA (2008-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

New OXY-variants from Klebisiella oxytoca Bloodculture Clinical Isolates Collected in USA Hospitals, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Oritavancin Using Fastidious and non-Fastidious Gram-Positive Organisms, Lead author: Holliday, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and non-Fastidious Gram- Positive Organisms, Lead author: Holliday, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Ceftaroline-Avibactam Tested Against Contemporary Clinical Isolates from USA Medical Centers (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Avibactam Reverts the Ceftazidime (CAZ) MIC₉₀ of a Recent Set of European Clinical Isolates of Gram-negative Bacteria Back to the Epidemiological Cut-off Value, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Spectrum and Potency of Ceftaroline-Avibactam Tested Against ESBL-Phenotype and Carbapenem-Resistant Enterobacteriaceae Collected from USA Hospitals (2009-2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of BAL30072, Alone and in Combination with Meropenem Tested Against Gram-Negative Bacteria Causing Serious Infections in Hospitals from China, India, Latin America and South East Asia-Pacific, Lead author: Rhomberg PR, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of the Novel Antimicrobial Ceftolozane/Tazobactam Tested Against Contemporary Clinical Strains from USA Hospitals (2011), Lead author: Sader HS, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity of Six Seachaid Pharmaceuticals Investigational Compounds Tested against Gram-positive Strains, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial Activity and Spectrum of a Seachaid Pharmaceuticals Investigational Compound (SP2078) Tested against Gram-positive Pathogens, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Time-kill and Post-antibiotic-effect studies of a Seachaid Pharmaceuticals Investigational Compound (SP2078) Against Wildtype and Multidrug-resistant Pathogens, Lead author: Mendes RE, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against a Global Collection of Acinetobacter spp. Including Multi-Drug Resistant (MDR) Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10 In Vitro Activity Tested Against Pathogens Commonly Associated with Community-Acquired Bacterial Pneumonia Infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

KPI-10, a Novel Fluoroquinolone Tested Against Neisseria gonorrhoeae including Ciprofloxacin Non-Susceptible and Penicillin Non-Susceptible Strains, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

In Vitro Activity of KPI-10 Tested Against Pathogens Commonly Associated with Urinary Tract infections, Lead author: Flamm R, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of RPX2003/RPX7009 (RPX3/9), a Carbapenem Combined with a Novel &#223-lactamase Inhibitor Tested Against Clinical Isolates Producing Defined Enzymes, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Pre-clinical Evaluation of a Carbapenem/ß-Lactamase Inhibitor Combination (RPX2003/RPX7009) Tested Against Serine-carbapenemase-producing Pathogens, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Activity of MK-3118, a New Oral Glucan Synthase Inhibitor, Tested Against Aspergillus spp. using Two Reference Broth Microdilution Methods, Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

New CLSI Clinical Breakpoints and Epidemiological Cutoff Values Applied to Characterize Resistance in the SENTRY Antifungal Surveillance Program (2010-2011), Lead author: Castanheira M, presented at 52nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 9 – 12, 2012, San Francisco, CA

Antimicrobial activity of ceftaroline and comparator agents tested against contemporary (2010) Staphylococcus aureus, including MRSA isolates, from Latin America, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial activity of ceftaroline/avibactam tested against clinical Enterobacteriaceae isolates carrying multiple &#223-lactamases from USA medical centers, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Interim Susceptibility Testing for Ceftaroline (CPT), a Novel MRSA-Active Cephalosporin: Selecting Potent Surrogate &#223-Lactam Markers to Predict CPT Activity against Clinically Indicated Species, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Candida famata as a Cause of Invasive Candidiasis: Misidentification in Two Global Surveillance Systems, Lead author: Castanheira M, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Contemporary Potencies of Minocycline (MIN) and Tetracycline (TET) Tested Against Gram-positive Pathogens: SENTRY Program Results using CLSI and EUCAST Breakpoint Criteria, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Influence of Surfactant (Polysorbate-80) on Susceptibility Testing Results for the Polymyxins Using Broth Microdilution Methods, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA